Abstract
Currently available data on drug coated balloon (DCB) angioplasty as a clinical treatment modality for coronary and peripheral artery disease are limited but hold promise. Advantages over standard angioplasty and stent technologies include a homogeneous drug delivery to the vessel wall, an immediate drug release without the use of a polymer, the option of using balloon catheters alone or in combination with a bare metal stent, no foreign object left behind in the body, the potential of reducing anti-platelet therapy, and a lower restenosis rates in some indications. The clinical and angiographic presentation of patients with acute coronary syndromre (ACS) is heterogeneous. Therefore, different clinical scenarios of DCB application in ACS may be discussed. Frequently, thrombosis in the ACS-related lesion plays a major role. Patients in hemodynamic critical situations under catecholamine therapy may present with too small vessel diameters. Another clinically relevant scenario represents in-stent restenosis (ISR) which is frequently associated with ACS.
Keywords: Drug coated balloon, acute coronary syndrome, thrombus containing lesion, angioplasty, coronary artery disease, thrombosis, stent, restenosis, chronic inflammation, myocardial infarction
Current Vascular Pharmacology
Title:Drug Coated Balloons in Acute Coronary Syndromes - Opportunities and Limitations
Volume: 10 Issue: 4
Author(s): Bruno Scheller, Yvonne Clever, Michael Bohm and Bodo Cremers
Affiliation:
Keywords: Drug coated balloon, acute coronary syndrome, thrombus containing lesion, angioplasty, coronary artery disease, thrombosis, stent, restenosis, chronic inflammation, myocardial infarction
Abstract: Currently available data on drug coated balloon (DCB) angioplasty as a clinical treatment modality for coronary and peripheral artery disease are limited but hold promise. Advantages over standard angioplasty and stent technologies include a homogeneous drug delivery to the vessel wall, an immediate drug release without the use of a polymer, the option of using balloon catheters alone or in combination with a bare metal stent, no foreign object left behind in the body, the potential of reducing anti-platelet therapy, and a lower restenosis rates in some indications. The clinical and angiographic presentation of patients with acute coronary syndromre (ACS) is heterogeneous. Therefore, different clinical scenarios of DCB application in ACS may be discussed. Frequently, thrombosis in the ACS-related lesion plays a major role. Patients in hemodynamic critical situations under catecholamine therapy may present with too small vessel diameters. Another clinically relevant scenario represents in-stent restenosis (ISR) which is frequently associated with ACS.
Export Options
About this article
Cite this article as:
Scheller Bruno, Clever Yvonne, Bohm Michael and Cremers Bodo, Drug Coated Balloons in Acute Coronary Syndromes - Opportunities and Limitations, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812692
DOI https://dx.doi.org/10.2174/157016112800812692 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does Handle Region Peptide Provide Benefits in Chronic Kidney Disease?
Current Hypertension Reviews Expression and Function of Anti-Inflammatory Interleukins: The Other Side of the Vascular Response to Injury
Current Vascular Pharmacology Adrenomedullins: Therapeutic Potential in Cardiovascular Disease
Current Hypertension Reviews Outcomes of Liver Transplantation from Deceased Donors with Coronavirus- Disease 2019 and Late Complications of Infection
Current Respiratory Medicine Reviews Meet Our Editor
Cardiovascular & Hematological Agents in Medicinal Chemistry Hypertension and Compliance to Treatment in the Primary Care Setting: Key Issues from the Literature Review
Current Hypertension Reviews Evaluation of B Lymphocyte Deficiencies
Cardiovascular & Hematological Disorders-Drug Targets Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects
Current Drug Metabolism The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets Nano-medicine Improving the Bioavailability of Small Molecules for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design A Review of the Current Role of Blood Clotting Analyzers in Clinical Practice
Cardiovascular & Hematological Disorders-Drug Targets Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Correlation Between Plasma Levels of RIP3 and Acute Ischemic Stroke with Large-Artery Atherosclerosis
Current Neurovascular Research Endothelial Dysfunction and Coronary Vasoreactivity - A Review of the History, Physiology, Diagnostic Techniques, and Clinical Relevance
Current Cardiology Reviews The Challenges in Moving from Ageing to Successful Longevity
Current Vascular Pharmacology New Insights of Early Brain Injury after Subarachnoid Hemorrhage: A Focus on the Caspase Family
Current Neuropharmacology Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry Myasthenia Gravis and Vitamin D Serum Levels: A Systematic Review and Meta-analysis
CNS & Neurological Disorders - Drug Targets Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery